- In April 2024, Dexcom, Inc. received CE Mark approval for its G7 Continuous Glucose Monitoring (CGM) System across Europe. The G7 system is a next-generation wearable blood glucose sensor patch that offers smaller size, faster warm-up time, and improved accuracy compared to its predecessor. The launch enables real-time glucose monitoring with smartphone integration, driving adoption among patients with diabetes seeking convenient, non-invasive solutions.
- In February 2024, Abbott Laboratories announced that its FreeStyle Libre 3 received expanded reimbursement coverage under Germany’s statutory health insurance (SHI) system. This development significantly increases access to sensor-based glucose monitoring for both Type 1 and insulin-treated Type 2 diabetes patients, further positioning Abbott as a market leader in wearable glucose monitoring patches in Europe.
- In October 2023, Medtronic plc launched the Simplera™ CGM sensor in select global markets. The Simplera is a fully disposable, all-in-one continuous glucose sensor patch designed for easy self-application, targeting users in both clinical and at-home settings. This reflects the industry’s push toward more user-friendly, accessible sensor technologies for long-term diabetes management.
- In September 2023, Senseonics Holdings, Inc. received FDA approval for its Eversense E3 CGM system, offering a 180-day wear duration, the longest currently available. The sensor patch is implantable and includes a removable transmitter, representing a novel approach in the CGM segment and appealing to patients looking for extended-use, low-maintenance options
